INTERVENTIONS FOR IMPROVING OUTCOMES OF CHILDREN WHO ARE DEAF OR HARD OF HEARING
Professor Teresa Y C Ching
Professorial Fellow, NextSense Institute, Sydney;
Conjoint Professor, Macquarie University, Sydney;
Honorary Professor, University of Queensland, Brisbane, Australia
RESEARCHER PROFILE
Filmed in Sydney | June 2025
About two to six per thousand children have a hearing loss that prevents them from achieving their full potential in life. They experience many more difficulties in cognitive, language and social development than their hearing peers. We know that early detection through newborn hearing screening is crucial, but less is known about how intervention can best be targeted to meet the needs of individual children and their families.
Professor Teresa Ching has led population-based studies that drive evidence-based practice in intervention for improving outcomes of children who are deaf or hard of hearing. Much of her research findings have been translated into practice and policy. However, many children from culturally and linguistically diverse backgrounds remain vulnerable, requiring intervention tailored to their needs. Furthermore, many children have undetected, untreated hearing problems when they enter school, thereby reducing their educational attainment and social participation.
Teresa is a Conjoint Professor at NextSense Institute and Macquarie University, and an Honorary Professor at the University of Queensland in Australia. Her current research focuses on devising culturally sensitive practices in early detection and intervention to maximise children’s outcomes. Working with international colleagues, her current research is also directed towards developing global guidelines and recommendations for hearing screening beyond the newborn period, so that all children can benefit from early detection and intervention. The ultimate goal is to attain equity of care and outcomes for all children with hearing difficulties.
Source: Supplied
-
Trials in treating STIs, vaccines and lipid lowering medications
Since joining Paratus Clinical Research in 2022, Dr Pi Lip Seet has served as both Principal Investigator and Sub-Investigator across Phase I–IV industry-sponsored clinical trials. His research experience spans vaccines, immunology, cardiovascular and endocrine disease, respiratory medicine, gastroenterology, pain management, sleep medicine and adult psychiatry. He has been involved in multiple vaccine development programs, including RSV, influenza, COVID-19, herpes zoster and pneumococcal studies.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
-
Genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia
Prof Deborah White’s research focus is genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia (ALL) and Chronic Myeloid Leukaemia (CML) and she holds peer reviewed grants from: The William Lawrence and Blanche Hughes Foundation and the Leukemia Lymphoma Society (USA), the NHMRC, the Leukaemia Foundation Australia (LFA), Channel 7, Cancer Australia, Tour de Cure and the Cancer Council SA (CCSA). Professor White has presented more than 170 papers at scientific meetings, and authored more than 100 scientific publications as well as being an inventor on several international patents.
